Patent review analyzes advancements in PTP1B inhibitors for diabetes treatment, suggesting future development pathways.
There has been tremendous progress in PTP1B drug discovery. Progress has been made with natural products, semi-synthetic natural product derivatives and heterocyclic hybrid compounds. A number of protocols are being pursued in order to enhance the biological effects of PTP1B inhibitors. In addition, these new advances suggest that it may be possible to obtain small molecule inhibitors of PTP1B with the required potency and selectivity. In addition, future efforts using an integrated medicinal chemistry and structural biology strategy are expected to lead to potent and selective PTP1B inhibitors.
No takes yet. Share an insight, caveat, or question.
Ashfaq et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: